Array Biopharma Inc news

   Watch this stock
Showing stories 11 - 20 of about 85   

Articles published

ARRY 6.32 +0.04 (0.72%)
price chart
Array BioPharma Inc. (NASDAQ:ARRY) Insider Trading Report
Array BioPharma Inc. (NASDAQ:ARRY) has a 1 Year Target Estimate of $8. The stock traded with the volume of 101.44 Million in the last trading session.
Bank of America Corp (NYSE:BAC)'s stock gain as much as 0.27 percent to ...  Investors News
Array BioPharma Inc. (NASDAQ:ARRY) Stock Declines, Analysts: Buy Rating
Array BioPharma Inc. (NASDAQ:ARRY) up 1.61% for the past 5 days, is under coverage of 0 analysts who collectively assign a buy rating on stock.
Recap of Insider Trading: Array BioPharma Inc. (NASDAQ:ARRY)  Street Updates
Stock under Review - Array BioPharma Inc.'s (ARRY)  Hot Stocks Point
Comprehensive Stock Analysis of: Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. (NASDAQ:ARRY) reported its last earnings on Aug 04 BMO (BMO = before market open, AMC= after market close).
Notable Insider Trading: Array Biopharma (ARRY)  The Voice Registrar
Array BioPharma Inc. (ARRY) Hits New 52-week High During September 27 Session
Array BioPharma Inc. (ARRY) hit a new 52-week high yesterday, reaching a peak of $7.27 after opening at $7.26 and closing at $6.59 for a move of -0.3%.
Array BioPharma Announces FDA Acceptance of Binimetinib NDA for Patients with ...
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
FDA Accepts Array BioPharma's NDA For Its Binimetinib  Benzinga
Array BioPharma Announces Phase 3 BEACON CRC SPA Agreement with FDA
14, 2016 /PRNewswire/ -- Array BioPharma (Nasdaq: ARRY) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) related to BEACON CRC, a global Phase 3 trial ...
Array Secures SPA Agreement With FDA for Colorectal Cancer Trial (ARRY)  Investopedia
Analysts: Array BioPharma Inc. (NASDAQ:ARRY) stock is worth $8
Array BioPharma Inc. (NASDAQ:ARRY) up 7% for the past 5 days, is under coverage of 8 analysts who collectively assign a buy rating on stock.
It's Earnings Time: What to Do with Array BioPharma Inc. (NASDAQ:ARRY) Stock  The Voice Registrar
Healthcare Names On Frontline: Array BioPharma Inc. (NASDAQ:ARRY), Vertex ...  TWN
Analysts Trends to Watch: Array BioPharma Inc. (NASDAQ:ARRY)
On 9/27/2016, shares of Array BioPharma Inc. (NASDAQ:ARRY) fell -0.30% in trading session and finally closed at $6.59. The company most recent volume stood at 51.27 million shares as compared to average volume of 4.29 million shares.
Array BioPharma Inc Realized Volatility Hits A Towering High
This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Array BioPharma Inc (NASDAQ:ARRY) . We also look at broad measures of the S&P 500 and Nasdaq 100 indices ...
Array BioPharma Continues Its Silent Rally With Mid-Stage Trial Win
Shares of Array BioPharma Inc. (NASDAQ: ARRY) saw a handy gain in Tuesdays session following the announcement of mid-stage results from its cardiomyopathy trial.
Array BioPharma Inc. (ARRY) Given New $7.00 Price Target at Jefferies Group  The Cerbat Gem
Worth Watching Stock: Array BioPharma Inc. (NASDAQ:ARRY)  News Oracle